Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?

Bibliography

• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189(11):1747-56
   PubMed Web of Science ®Google Scholar
• Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 2012;64(7):595-602
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61(9):1143-51
   PubMed Web of Science ®Google Scholar
• Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012;30(1):69-77
   PubMed Web of Science ®Google Scholar
• A randomized, double blind, baseline controlled study using placebo as reference for assessing the efficacy and safety of hydroxychloroquine sulfate in patients with systemic lupus erythematosus or cutaneous lupus erythematosus in the presence of active lupus erythematosus specific skin lesion. Available from: http://clinicaltrials.gov/ct2/show/NCT01551069
   Google Scholar
• Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005;44(6):1919-31
   PubMed Web of Science ®Google Scholar
• Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65
   PubMed Web of Science ®Google Scholar
• Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72(9):1453-60
   PubMed Web of Science ®Google Scholar
• Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71(11):1833-8
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90
   PubMed Web of Science ®Google Scholar
• Development of a quantitative PCR method to determine interferon signature metric status in sle patients: distribution and clinical & serological associations in two lupus clinical trials. ACR/ARHP Annual Meeting Publications; 2012. Abstract Supplement available from http://www.rheumatology.org/publications/acr_arhp_annual_meeting.asp
   Google Scholar
• Efficacy and safety of atacicept for prevention of flares in patients with moderate to severe systemic lupus erythematosus (SLE): 52-Wk Data (APRIL-SLE Trial). EULAR Annual European Congress of Rheumatology; 2013. Available from: http://www.abstracts2view.com/eular/view.php?nu=EULAR13L_THU0276
   Google Scholar
• Blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus. Am Coll Rheumatol 2012; Abstract Supplement available from http://www.rheumatology.org/publications/acr_arhp_annual_meeting.asp
   Google Scholar
• Ginzler EM, Wax S, Rajeswaran A. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14(1):R33
   PubMed Web of Science ®Google Scholar
• A Phase IIb, multi-center, randomized, double-blind, placebo-controlled, multidose, 24-week study to evaluate the efficacy and safety of atacicept in subjects with systemic lupus erythematosus (SLE). Available from: http://clinicaltrials.gov/ct2/show/NCT01972568
   Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65(9):2368-79
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013;65(2):447-56
   PubMed Web of Science ®Google Scholar
• Results of a randomized, placebo-controlled, phase 2a study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus. Annual European congress of Rheumatology Publication; 2011. Abstract available from http://www.abstracts2view.com/eular/view.php?nu=EULAR11L_THU0411&terms=
   Google Scholar
• Efficacy and safety of rontalizumab (anti-interferon alpha) in sle subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. ACR/ARHP Annual Meeting Publications; 2012. Abstract supplement Available from http://www.rheumatology.org/publications/acr_arhp_annual_meeting.asp
   Google Scholar
• Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111(5):2755-64
   PubMed Web of Science ®Google Scholar
• Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21
   PubMed Web of Science ®Google Scholar
• Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):578-82
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgoes-Vargas R, Westhoven R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10):3077-87
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, controlled, phase ii multicenter trial of ctla4ig (abatacept) plus cyclophosphamide vs cyclophosphamide alone in the treatment of lupus nephritis. Available from: http://clinicaltrials.gov/ct2/show/NCT00774852
   Google Scholar
• Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013;52(7):1313-22
   PubMed Web of Science ®Google Scholar
• Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013;15(Suppl 1):S2
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 2013;27(3):341-9
   PubMed Web of Science ®Google Scholar
• Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013;22(11):1142-9
   PubMed Web of Science ®Google Scholar
• Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010;12(Suppl 1):S5
   PubMedGoogle Scholar
• Shrivastav M, Niewold TB. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013;4:319
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, placebo-controlled, single dose, two-period, crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of amg 811 in subjects with discoid lupus erythematosus. Available from: http://clinicaltrials.gov/show/NCT01164917
   Google Scholar
• A Phase 1b, randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of amg 811 in subjects with systemic lupus erythematosus with and without glomerulonephritis. Available from: http://clinicaltrials.gov/ct2/show/NCT00818948
   Google Scholar
• First in human study of an anti-ifn gamma monoclonal antibody in healthy volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01459562
   Google Scholar